Review of the Multicenter Trial Committee report : a prospective , randomized study on the prophylaxis of <font color="red">postoperative_1</font> <font color="red">deep_1</font> <font color="red">venous_1</font> <font color="red">thrombosis_1</font> <font color="red">._1</font> 
<br>
<br> The etiology of <font color="red">postoperative_1</font> <font color="red">deep_1</font> <font color="red">venous_1</font> <font color="red">thrombosis_1</font> <font color="red">(_1</font> <font color="red">DVT_1</font> <font color="red">)_1</font> is thought to be due to a combination of factors including stasis , a hypercoagulable state and venous endothelial damage . Methods of prophylaxis are directed toward correcting one or more of these pathologic events . Methods counteracting more than one of these factors can be expected to be even more effective . The combination of dihydroergotamine ( DHE ) and heparin was anticipated to minimize stasis and the hypercoagulable state respectively . Based upon current experimental evidence and current theory , an additional benefit might include minimizing venous endothelial injury by controlling venomotor tone . A prospective , randomized , double - blind , multicenter trial was designed and performed in the <font color="red">United_1</font> <font color="red">States_1</font> evaluating the prophylactic efficacy of DHE 0.5 mg plus heparin 5000 U , DHE 0.5 mg plus heparin 2500 U , heparin 5000 U , and DHE 0.5 mg versus placebo . <font color="red">General_2</font> <font color="red">surgical_2</font> <font color="red">patients_2</font> <font color="red">including_2</font> <font color="red">those_2</font> <font color="red">undergoing_2</font> <font color="red">noncardiac_2</font> <font color="red">thoracic_2</font> <font color="red">and_2</font> <font color="red">pelvic_2</font> <font color="red">operations_2</font> <font color="red">who_2</font> <font color="red">were_2</font> <font color="red">identified_2</font> <font color="red">at_2</font> <font color="red">moderate_2</font> <font color="red">to_2</font> <font color="red">high_2</font> <font color="red">risk_2</font> <font color="red">for_2</font> <font color="red">postop_2</font> <font color="red">DVT_2</font> <font color="red">were_1</font> <font color="red">included_1</font> <font color="red">._1</font> Study medications were injected subcutaneously two hours preoperatively and every 12 hours postoperatively for 5 - 7 days or until the 125I - fibrinogen - uptake test ( RFUT ) became positive . <font color="red">Eight_1</font> <font color="red">hundred_1</font> <font color="red">and_1</font> <font color="red">eighty_1</font> <font color="red">eight_1</font> <font color="red">patients_1</font> <font color="red">were_1</font> <font color="red">entered_1</font> <font color="red">into_1</font> <font color="red">this_1</font> <font color="red">trial_1</font> <font color="red">and_1</font> <font color="red">744_1</font> <font color="red">(_1</font> <font color="red">85%_1</font> <font color="red">)_1</font> <font color="red">completed_1</font> <font color="red">the_1</font> <font color="red">study_1</font> <font color="red">._1</font> Results showed a statistically significant benefit from DHE / Hep 5000 compared to placebo ( p less than 0.01 ) and compared to other active agents ( p less than 0.05 ) . None of the other active agents showed a statistically significant prophylactic benefit.(ABSTRACT TRUNCATED AT 250 WORDS )